These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 12574398)
1. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398 [TBL] [Abstract][Full Text] [Related]
2. A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapies. Pincus SH; Fang H; Wilkinson RA; Olson WC; Marcotte TK AIDS Res Hum Retroviruses; 2003 Oct; 19(10):901-8. PubMed ID: 14585222 [TBL] [Abstract][Full Text] [Related]
3. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Pincus SH; McClure J Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938 [TBL] [Abstract][Full Text] [Related]
4. Rationale for the use of immunotoxins in the treatment of HIV-infected humans. Van Oijen MG; Preijers FW J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864 [TBL] [Abstract][Full Text] [Related]
5. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. Sanhadji K; Grave L; Touraine JL; Leissner P; Rouzioux C; Firouzi R; Kehrli L; Tardy JC; Mehtali M AIDS; 2000 Dec; 14(18):2813-22. PubMed ID: 11153662 [TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. Allaway GP; Ryder AM; Beaudry GA; Maddon PJ AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162 [TBL] [Abstract][Full Text] [Related]
7. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. Pincus SH; Wehrly K; Cole R; Fang H; Lewis GK; McClure J; Conley AJ; Wahren B; Posner MR; Notkins AL; Tilley SA; Pinter A; Eiden L; Teintze M; Dorward D; Tolstikov VV AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1041-51. PubMed ID: 8827220 [TBL] [Abstract][Full Text] [Related]
8. Selective killing of HIV-infected cells by anti-gp120 immunotoxins. Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K AIDS Res Hum Retroviruses; 1990 Feb; 6(2):193-203. PubMed ID: 2328157 [TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247 [TBL] [Abstract][Full Text] [Related]
11. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567 [TBL] [Abstract][Full Text] [Related]
12. Passive immunization for the prevention and treatment of HIV infection. Zolla-Pazner S; Gorny MK AIDS; 1992 Nov; 6(11):1235-47. PubMed ID: 1472330 [No Abstract] [Full Text] [Related]
13. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. McCaffrey RA; Saunders C; Hensel M; Stamatatos L J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849 [TBL] [Abstract][Full Text] [Related]
14. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249 [TBL] [Abstract][Full Text] [Related]
15. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412 [TBL] [Abstract][Full Text] [Related]
16. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. Cavacini LA; Emes CL; Wisnewski AV; Power J; Lewis G; Montefiori D; Posner MR AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1271-80. PubMed ID: 9764911 [TBL] [Abstract][Full Text] [Related]
17. [Human monoclonal antibodies to HIV-1 infection]. Kawai M; Okada N Nihon Rinsho; 2002 Mar; 60(3):570-7. PubMed ID: 11904975 [TBL] [Abstract][Full Text] [Related]
18. In vivo testing of anti-HIV immunotoxins. Pincus SH; Marcotte TK; Forsyth BM; Fang H Methods Mol Biol; 2001; 166():277-94. PubMed ID: 11217373 [No Abstract] [Full Text] [Related]
19. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner. Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974 [TBL] [Abstract][Full Text] [Related]
20. Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins. Tolstikov VV; Cole R; Fang H; Pincus SH Bioconjug Chem; 1997; 8(1):38-43. PubMed ID: 9026033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]